ClinicalTrials.gg

Program

povetacicept

Also written as “Povetacicept” and “ALPN-303”.

Its studies are mostly in Glomerulonephritis, IGA · Glomerulonephritis, Membranous · Myasthenia Gravis · Lupus Nephritis · Purpura, Thrombocytopenic, Idiopathic, led by Vertex Pharmaceuticals.

Furthest: phase 3, since Aug 19, 20249 company-led studies, 6 open or runningNext primary completion: Dec 12, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals96 open or runningphase 3since Aug 19, 2024Aug 26, 2021Dec 12, 2027phase 3 · NCT07890909

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05034484 · 72 enrolled · Australia
  2. Feb 8, 20232 phase 2 studiesNCT05732402, NCT05757570
  3. Aug 19, 2024Phase 3 study in Glomerulonephritis, IGANCT06564142 · 605 enrolled · United States, Australia, Austria and more
  4. May 30, 2025Phase 1 study in Healthy VolunteersNCT07010406 · 136 enrolled · United States
  5. Sep 24, 2025Phase 3 study in Primary Membranous NephropathyNCT07204275 · 176 planned · United States, Australia, Brazil and more
  6. Mar 24, 2026Phase 2 study in Myasthenia GravisNCT07501702 · 34 enrolled · United States, Australia, Poland and more
  7. Aug 20, 2026Phase 3 study in Glomerulonephritis, IGANCT07807995 · 605 planned · United States
  8. Oct 15, 2026Phase 3 study in Glomerulonephritis, IGANCT07890909 · 40 planned

Ahead

  1. Dec 12, 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT07890909
  2. Jan 30, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT06564142
  3. Mar 2, 2028Primary completion: phase 2 study in Lupus NephritisNCT05732402
  4. Dec 29, 2028Primary completion: phase 3 study in Primary Membranous NephropathyNCT07204275

TargetBeta

TNFRSF13B →read by rule
“An affinity-optimized Fc fusion protein composed of an engineered variant domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; TNF receptor superfamily 13B; transmembrane activator and CAML interactor; transmembrane activator and calcium modulator and cyclophilin ligand ”NCIt, by rule

Other programs on TNFRSF13B

ProgramCompanyFurthest phaseStudies
telitaciceptruleRemeGenphase 325
SHR-2173Jiangsu HengRui Medicinephase 28

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07890909Glomerulonephritis, IGA3Not yet recruitingDec 12, 202740
NCT07807995Glomerulonephritis, IGA · United States3By invitationDec 28, 2029605
NCT07501702Myasthenia Gravis · United States, Australia, Poland and more2Active, not recruitingMar 2, 202934
NCT07204275Primary Membranous Nephropathy · United States, Australia, Brazil and more3RecruitingDec 29, 2028176
NCT07010406Healthy Volunteers · United States1CompletedAug 19, 2025136
NCT06564142Glomerulonephritis, IGA · United States, Australia, Austria and more3Active, not recruitingJan 30, 2028605
NCT05757570Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Austria and more2CompletedAug 12, 202630
NCT05732402Lupus Nephritis · United States, Australia, Puerto Rico and more2Active, not recruitingMar 2, 202872
NCT05034484Healthy Volunteers · Australia1CompletedFeb 27, 202372

How it is read

Names in the registry

  • “Povetacicept”, 8 entries
  • “ALPN-303”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.